CU24130B1 - Isoquinolinonas y quinazolinonas sustituidas - Google Patents
Isoquinolinonas y quinazolinonas sustituidasInfo
- Publication number
- CU24130B1 CU24130B1 CU2012000098A CU20120098A CU24130B1 CU 24130 B1 CU24130 B1 CU 24130B1 CU 2012000098 A CU2012000098 A CU 2012000098A CU 20120098 A CU20120098 A CU 20120098A CU 24130 B1 CU24130 B1 CU 24130B1
- Authority
- CU
- Cuba
- Prior art keywords
- isoquinolinones
- quinazolinones
- replaced
- formula
- mdm4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a heterociclos bicíclicos que contienen nitrógeno sustituidos de la fórmula (I): ESPACIO PARA LA FÓRMULA en donde Z es CH2 o N-R4, y X, R1, R2, R4, R6, R7 y n son como se definen en la descripción. Estos compuestos son adecuados para el tratamiento de un trastorno o enfermedad que sea mediada por la actividad de MDM2 y/o MDM4, o variantes de los mismos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28899209P | 2009-12-22 | 2009-12-22 | |
| CN2010078927 | 2010-11-19 | ||
| PCT/EP2010/070364 WO2011076786A1 (en) | 2009-12-22 | 2010-12-21 | Substituted isoquinolinones and quinazolinones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20120098A7 CU20120098A7 (es) | 2012-10-15 |
| CU24130B1 true CU24130B1 (es) | 2015-09-29 |
Family
ID=45093718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2012000098A CU24130B1 (es) | 2009-12-22 | 2010-12-21 | Isoquinolinonas y quinazolinonas sustituidas |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US9073898B2 (es) |
| EP (1) | EP2640467B1 (es) |
| JP (1) | JP5667308B2 (es) |
| KR (1) | KR101561750B1 (es) |
| AR (1) | AR083905A1 (es) |
| AU (1) | AU2011331095B2 (es) |
| BR (1) | BR112013011966A2 (es) |
| CA (1) | CA2816810A1 (es) |
| CO (1) | CO6801719A2 (es) |
| CU (1) | CU24130B1 (es) |
| CY (1) | CY1116002T1 (es) |
| DK (1) | DK2640467T3 (es) |
| EC (1) | ECSP13012628A (es) |
| ES (1) | ES2528376T3 (es) |
| GT (1) | GT201300132A (es) |
| HK (1) | HK1184091A1 (es) |
| HR (1) | HRP20150231T1 (es) |
| IL (1) | IL226182A0 (es) |
| MA (1) | MA34666B1 (es) |
| ME (1) | ME02099B (es) |
| MX (1) | MX336634B (es) |
| MY (1) | MY160880A (es) |
| NZ (1) | NZ610296A (es) |
| PE (1) | PE20140420A1 (es) |
| PH (1) | PH12013500979A1 (es) |
| PL (1) | PL2640467T3 (es) |
| PT (1) | PT2640467E (es) |
| RS (1) | RS53770B1 (es) |
| RU (1) | RU2013127661A (es) |
| SG (1) | SG190186A1 (es) |
| SI (1) | SI2640467T1 (es) |
| SM (1) | SMT201500059B (es) |
| TW (1) | TWI520950B (es) |
| WO (1) | WO2012066095A1 (es) |
| ZA (1) | ZA201303155B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2939778C (en) | 2007-01-31 | 2019-01-29 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| EP2142562B1 (en) | 2007-03-28 | 2013-07-03 | President and Fellows of Harvard College | Stitched polypeptides |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| CN108570097A (zh) | 2010-08-13 | 2018-09-25 | 爱勒让治疗公司 | 拟肽大环化合物 |
| CN108929375A (zh) | 2011-10-18 | 2018-12-04 | 爱勒让治疗公司 | 拟肽大环化合物 |
| US9408885B2 (en) * | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| NZ627528A (en) | 2012-02-15 | 2016-05-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
| EP2819688A4 (en) | 2012-02-15 | 2015-10-28 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER |
| CN104321325B (zh) | 2012-05-24 | 2016-11-16 | 诺华股份有限公司 | 吡咯并吡咯烷酮化合物 |
| SG11201503052RA (en) | 2012-11-01 | 2015-05-28 | Aileron Therapeutics Inc | Disubstituted amino acids and methods of preparation and use thereof |
| EP2948451B1 (en) | 2013-01-22 | 2017-07-12 | Novartis AG | Substituted purinone compounds |
| US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
| EP3412675A1 (en) | 2013-05-27 | 2018-12-12 | Novartis AG | Imidazopyrrolidinone derivatives and their use in the treatment of disease |
| EP3004108B1 (en) | 2013-05-28 | 2017-10-18 | Novartis AG | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease |
| ES2650562T3 (es) | 2013-05-28 | 2018-01-19 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades |
| EA029269B1 (ru) | 2013-11-21 | 2018-02-28 | Новартис Аг | Производные пирролопирролона и их применение для лечения заболеваний |
| KR102283895B1 (ko) * | 2013-12-23 | 2021-07-30 | 노파르티스 아게 | 제약 조합물 |
| US20160339023A1 (en) * | 2013-12-23 | 2016-11-24 | Fang Li | Pharmaceutical Combinations |
| MX2017003797A (es) | 2014-09-24 | 2017-06-15 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
| CA2961029A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
| CA2979847A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| TWI804010B (zh) | 2015-08-03 | 2023-06-01 | 瑞士商諾華公司 | 作為血液學毒性生物標記之gdf-15 |
| CN108348611A (zh) * | 2015-08-28 | 2018-07-31 | 诺华股份有限公司 | 使用pi3k抑制剂和mdm2抑制剂的联合疗法 |
| RU2740091C2 (ru) | 2015-08-28 | 2021-01-11 | Новартис Аг | Ингибиторы mdm2 и их комбинации |
| WO2017044633A1 (en) | 2015-09-10 | 2017-03-16 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of mcl-1 |
| KR101838687B1 (ko) | 2016-01-26 | 2018-03-15 | 한국생명공학연구원 | 나노포어를 이용한 단백질-단백질 상호작용 저해제 스크리닝 방법 |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| SI3541387T1 (sl) | 2016-11-15 | 2021-08-31 | Novartis Ag | Odmerek in režim za zaviralce interakcije HDM2-P53 |
| WO2018092064A1 (en) | 2016-11-18 | 2018-05-24 | Novartis Ag | Combinations of mdm2 inhibitors and bcl-xl inhibitors |
| KR20190112263A (ko) | 2016-12-12 | 2019-10-04 | 멀티비르 인코포레이티드 | 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물 |
| WO2019053595A1 (en) | 2017-09-12 | 2019-03-21 | Novartis Ag | INHIBITORS OF PROTEIN KINASE C FOR THE TREATMENT OF CHOROIDAL MELLANOMA |
| WO2019073435A1 (en) | 2017-10-12 | 2019-04-18 | Novartis Ag | COMBINATIONS OF MDM2 INHIBITORS WITH ERK INHIBITORS TO TREAT CANCERS |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3829420A (en) | 1970-07-13 | 1974-08-13 | Sumitomo Chemical Co | 3,4-dihydro-2(1h)-quinazolinones and preparation thereof |
| US4099002A (en) | 1970-12-23 | 1978-07-04 | Sumitomo Chemical Company, Limited | Quinazolinone derivatives and a process for production thereof |
| JPS4822715B1 (es) | 1970-12-28 | 1973-07-07 | ||
| JPS5427356B2 (es) | 1972-03-31 | 1979-09-10 | ||
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| US4258187A (en) | 1977-06-16 | 1981-03-24 | E. I. Du Pont De Nemours And Company | Process for preparing quinazolinone oxides |
| US4335127A (en) | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
| DE3372965D1 (en) | 1982-07-23 | 1987-09-17 | Ici Plc | Amide derivatives |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| DE3420799A1 (de) | 1984-06-04 | 1985-12-05 | Bayer Ag, 5090 Leverkusen | Chromogene 4,4-diaryl-dihydrochinazolone, ihre herstellung und verwendung |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| AU2436792A (en) | 1991-08-16 | 1993-03-16 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| TW225528B (es) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| ES2309119T3 (es) | 1992-10-28 | 2008-12-16 | Genentech, Inc. | Utilizacion de antagonistas del factor de crecimiento celular vegf. |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| ATE205483T1 (de) | 1995-03-30 | 2001-09-15 | Pfizer | Chinazolinderivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| CN1100778C (zh) | 1995-07-06 | 2003-02-05 | 诺瓦蒂斯有限公司 | 吡咯并嘧啶及其制备方法 |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| WO1997038983A1 (en) | 1996-04-12 | 1997-10-23 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
| CA2258548C (en) | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| DE69738754D1 (de) | 1996-07-05 | 2008-07-17 | Cancer Rec Tech Ltd | Hemmer der interaktion zwischen p53 und mdm2 |
| JP2001500851A (ja) | 1996-08-30 | 2001-01-23 | ノバルティス アクチエンゲゼルシャフト | エポシロンの製造法および製造過程中に得られる中間生産物 |
| WO1998010121A1 (en) | 1996-09-06 | 1998-03-12 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| DE59712968D1 (de) | 1996-11-18 | 2008-10-30 | Biotechnolog Forschung Gmbh | Epothilone E und F |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| DE69927790T2 (de) | 1998-02-25 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen |
| ES2342240T3 (es) | 1998-08-11 | 2010-07-02 | Novartis Ag | Derivados de isoquinolina con actividad que inhibe la angiogenia. |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| KR20070087132A (ko) | 1998-11-20 | 2007-08-27 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법및 물질 |
| AU775806B2 (en) | 1998-12-22 | 2004-08-19 | Genentech Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
| ES2265929T3 (es) | 1999-03-30 | 2007-03-01 | Novartis Ag | Derivados de ftalazina para el tratamiento de enfermedades inflamatorias. |
| WO2000066560A1 (en) | 1999-05-04 | 2000-11-09 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| JP2001302515A (ja) | 2000-04-18 | 2001-10-31 | Sumitomo Pharmaceut Co Ltd | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤 |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| EP1513522A2 (en) | 2002-01-18 | 2005-03-16 | Sri International | Methods of treating conditions associated with an edg receptor |
| AU2003235504A1 (en) | 2002-05-13 | 2003-11-11 | 3-Dimensional Pharmaceuticals, Inc. | Method for cytoprotection through mdm2 and hdm2 inhibition |
| US7119111B2 (en) | 2002-05-29 | 2006-10-10 | Amgen, Inc. | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use |
| US20040213264A1 (en) | 2003-04-25 | 2004-10-28 | Nortel Networks Limited | Service class and destination dominance traffic management |
| WO2005019188A1 (ja) | 2003-08-22 | 2005-03-03 | Takeda Pharmaceutical Company Limited | 縮合ピリミジン誘導体およびその用途 |
| PT1663185E (pt) | 2003-09-22 | 2009-02-16 | Onepharm Res & Dev Gmbh | Prevenção e tratamento de perda óssea induzida por inflamação e/ou imunomediada |
| GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| EP1868685A2 (en) | 2005-03-18 | 2007-12-26 | onepharm GmbH | 11ß-HYDROXYSTEROID DEHYDROGENASES |
| US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| DE102006016426A1 (de) | 2006-04-07 | 2007-10-11 | Merck Patent Gmbh | Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren |
| WO2008034039A2 (en) | 2006-09-15 | 2008-03-20 | Nexuspharma Inc. | Novel tetrahydro-isoquinolines |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
-
2010
- 2010-12-21 CU CU2012000098A patent/CU24130B1/es active IP Right Grant
-
2011
- 2011-11-17 MY MYPI2013001567A patent/MY160880A/en unknown
- 2011-11-17 RS RS20150050A patent/RS53770B1/en unknown
- 2011-11-17 WO PCT/EP2011/070385 patent/WO2012066095A1/en active Application Filing
- 2011-11-17 PL PL11790916T patent/PL2640467T3/pl unknown
- 2011-11-17 MX MX2013005631A patent/MX336634B/es unknown
- 2011-11-17 DK DK11790916.8T patent/DK2640467T3/en active
- 2011-11-17 NZ NZ610296A patent/NZ610296A/en not_active IP Right Cessation
- 2011-11-17 JP JP2013539265A patent/JP5667308B2/ja not_active Expired - Fee Related
- 2011-11-17 AR ARP110104289A patent/AR083905A1/es unknown
- 2011-11-17 RU RU2013127661/04A patent/RU2013127661A/ru not_active Application Discontinuation
- 2011-11-17 EP EP11790916.8A patent/EP2640467B1/en active Active
- 2011-11-17 PH PH1/2013/500979A patent/PH12013500979A1/en unknown
- 2011-11-17 SI SI201130417T patent/SI2640467T1/sl unknown
- 2011-11-17 PT PT11790916T patent/PT2640467E/pt unknown
- 2011-11-17 CA CA2816810A patent/CA2816810A1/en not_active Abandoned
- 2011-11-17 KR KR1020137015727A patent/KR101561750B1/ko not_active IP Right Cessation
- 2011-11-17 BR BR112013011966A patent/BR112013011966A2/pt not_active IP Right Cessation
- 2011-11-17 ME MEP-2015-12A patent/ME02099B/me unknown
- 2011-11-17 US US13/988,227 patent/US9073898B2/en not_active Expired - Fee Related
- 2011-11-17 ES ES11790916.8T patent/ES2528376T3/es active Active
- 2011-11-17 PE PE2013001210A patent/PE20140420A1/es not_active Application Discontinuation
- 2011-11-17 US US13/298,351 patent/US8969351B2/en not_active Expired - Fee Related
- 2011-11-17 SG SG2013034988A patent/SG190186A1/en unknown
- 2011-11-17 AU AU2011331095A patent/AU2011331095B2/en not_active Ceased
- 2011-11-18 TW TW100142392A patent/TWI520950B/zh not_active IP Right Cessation
-
2013
- 2013-04-30 ZA ZA2013/03155A patent/ZA201303155B/en unknown
- 2013-05-06 IL IL226182A patent/IL226182A0/en unknown
- 2013-05-14 MA MA35904A patent/MA34666B1/fr unknown
- 2013-05-17 EC ECSP13012628 patent/ECSP13012628A/es unknown
- 2013-05-17 GT GT201300132A patent/GT201300132A/es unknown
- 2013-05-24 CO CO13128275A patent/CO6801719A2/es not_active Application Discontinuation
- 2013-10-11 HK HK13111501.4A patent/HK1184091A1/xx not_active IP Right Cessation
-
2015
- 2015-02-12 CY CY20151100140T patent/CY1116002T1/el unknown
- 2015-02-27 HR HRP20150231AT patent/HRP20150231T1/hr unknown
- 2015-03-10 SM SM201500059T patent/SMT201500059B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20120098A7 (es) | Isoquinolinonas y quinazolinonas sustituidas | |
| NI201200111A (es) | Isoquinolinonas y quinazolinonas sustituidas | |
| DOP2013000027A (es) | Derivados de tetrahidro-pirido-pirimidina | |
| CR11757A (es) | Compuestos de triazina como inhibidores mtor y quinasa pi3 | |
| GT200700046A (es) | Nuevos microbiocidas | |
| CR20110257A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes | |
| CO6390057A2 (es) | Indazoles oxazol sustituidos como inhibidores de pi3-quinasa | |
| UY31072A1 (es) | Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido | |
| PA8795701A1 (es) | Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3 | |
| GT200600422A (es) | Derivados de carboxamida como antagonistas del receptor muscarinico | |
| SV2010003648A (es) | Inhibidores del receptor de quimioquinas cxcr3 | |
| BRPI0906522A2 (pt) | Sulfonamidas como antagonistas de orexina | |
| CO6300951A2 (es) | Derivados de azaciclilisoquinolinona e- isoindolinona como antagonistas de la histamina-3 | |
| CR10060A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
| CU24325B1 (es) | Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores | |
| CR20110368A (es) | Compuestos de quinazolina sustituidos | |
| CY1115071T1 (el) | Συνδυασμος ο οποιος περιεχει πακλιταξελη για τη θεραπευτικη αντιμετωπιση του καρκινου των ωοθηκων | |
| ECSP13012495A (es) | Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina | |
| BRPI0916657A2 (pt) | pirrolidin-3-ilmetil-amina como antagonistas de orexina | |
| UY31840A (es) | Pirrolidin amidas sustituidas como moduladores del receptor histamina h3 | |
| UY31646A1 (es) | Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico | |
| EP4178505A4 (en) | FOOD INTAKE OF INJECTABLE MUSHROOM | |
| CY1115899T1 (el) | Υποκατεστημενες ισοκινολινονες και κιναζολινονες | |
| CU20080116A7 (es) | 3-aminociclopentanocarboxamidas como muduladores de receptores de quimioquinas | |
| CU23642B7 (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant of patent |